Related Experiment Video
Updated: Jan 1, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Management of Hyperlipidemia After Stroke
Daniel C Brooks1, Joseph L Schindler2
1Department of Internal Medicine, Division of Neurology, Stamford Health Medical Group and Stamford Hospital, Stamford, CT, USA.
Insights
Hyperlipidemia management is crucial for stroke prevention. Statins are first-line, with PCSK9 inhibitors and ezetimibe offering additional stroke risk reduction when added to statins for high-risk patients.
Area of Science:
- Cardiovascular Medicine
- Neurology
- Pharmacology
Background:
- Hyperlipidemia is a significant risk factor for stroke.
- Effective management of lipid levels is essential for cardiovascular health and stroke risk reduction.
Purpose of the Study:
- To review current treatment options for hyperlipidemia.
- To evaluate the efficacy of these treatments in preventing stroke, considering general cardiovascular disease and specific stroke subtypes (ischemic and hemorrhagic).
Main Methods:
- Literature review of clinical trials and studies on hyperlipidemia treatments.
- Analysis of treatment efficacy data, focusing on stroke risk reduction.
Main Results:
- Statins are the primary treatment for hyperlipidemia to prevent stroke.
- PCSK9 inhibitors and ezetimibe, when added to statins, provide further stroke risk reduction in patients with atherosclerotic vascular disease.
- Aggressive low-density lipoprotein cholesterol (LDL-C) reduction is key for high-risk patients.
Conclusions:
- Hyperlipidemia is a modifiable target for stroke risk reduction.
- Combination therapy with statins and novel agents like PCSK9 inhibitors or ezetimibe can significantly decrease stroke risk.
- Identifying patients who benefit from intensive lipid-lowering strategies is critical for stroke prevention.
Purpose Of Review:
Hyperlipidemia is a key therapeutic target for stroke risk modification. The goal of this review is to highlight available treatment options and review their efficacy in the setting of general cardiovascular disease and after most subtypes of ischemic stroke and hemorrhagic stroke.
Recent Findings:
Statins remain first-line in the management of hyperlipidemia to prevent stroke. In recent trials of patients with pre-existing atherosclerotic vascular disease, new agents, most notably PCSK9 inhibitors and ezetimibe, added additional stroke risk reduction when combined with statins. Risk of stroke can be significantly reduced by understanding that hyperlipidemia is a key therapeutic target, particularly in patients with cardiovascular disease, and by identifying patients who may benefit from aggressive LDL-C reduction with statins ± novel agents.
More Related Videos
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis IV: Nursing Management
Angina IV: Management
Coronary Artery Disease IV: Preventive Measures
Peripheral Artery Disease III: Interprofessional Care

